Page last updated: 2024-11-12

protopanaxatriol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

protopanaxtriol: a cardioprotective agent isolated from Panax notoginseng; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

protopanaxatriol: triterpenoid sapogenin of ginsenosides from leaves of Panax ginseng; acid hydrolysis leads to panaxatriol [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

protopanaxatriol : A tetracyclic triterpenoid sapogenin (isolated from ginseng and notoginseng) that is that is dammarane which is substituted by hydroxy groups at the 3beta, 6alpha, 12beta and 20 pro-S positions and in which a double bond has been introduced at the 24-25 position. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

FloraRankFlora DefinitionFamilyFamily Definition
PanaxgenusAn araliaceous genus of plants that contains a number of pharmacologically active agents used as stimulants, sedatives, and tonics, especially in traditional medicine. Sometimes confused with Siberian ginseng (ELEUTHEROCOCCUS).[MeSH]AraliaceaeThe ginseng plant family of the order Apiales, subclass Rosidae, class Magnoliopsida. Leaves are generally alternate, large, and compound. Flowers are five-parted and arranged in compound flat-topped umbels. The fruit is a berry or (rarely) a drupe (a one-seeded fruit). It is well known for plant preparations used as adaptogens (immune support and anti-fatigue).[MeSH]
PanaxgenusAn araliaceous genus of plants that contains a number of pharmacologically active agents used as stimulants, sedatives, and tonics, especially in traditional medicine. Sometimes confused with Siberian ginseng (ELEUTHEROCOCCUS).[MeSH]AraliaceaeThe ginseng plant family of the order Apiales, subclass Rosidae, class Magnoliopsida. Leaves are generally alternate, large, and compound. Flowers are five-parted and arranged in compound flat-topped umbels. The fruit is a berry or (rarely) a drupe (a one-seeded fruit). It is well known for plant preparations used as adaptogens (immune support and anti-fatigue).[MeSH]

Cross-References

ID SourceID
PubMed CID11468733
CHEMBL ID255683
CHEBI ID75951
SCHEMBL ID12935862
MeSH IDM0217499
PubMed CID134688663
MeSH IDM0217499

Synonyms (32)

Synonym
34080-08-5
20(s)-protopanaxatriol ,
zmk19p3wmp ,
dammar-24-ene-3,6,12,20-tetrol, (3beta,6alpha,12beta)-
unii-zmk19p3wmp
protopanaxtriol
dammar-24-ene-3beta,6alpha,12beta,20-tetrol
CHEBI:75951 ,
(3beta,6alpha,12beta)-dammar-24-ene-3,6,12,20-tetrol
(20s)-protopanaxatriol
HY-N0835
SCHEMBL12935862
C20716
protopanaxatriol-type ginsenoside aglycone
AC-33941
CHEMBL255683
panaxoside a aglycone a.phi.
dammar-24-ene-3.beta.,6.alpha.,12.beta.,20-tetrol, (20s)-
dammar-24-ene-3,6,12,20-tetrol, (3.beta.,6.alpha.,12.beta.)-
(3.beta.,6.alpha.,12.beta.)-dammar-24-ene-3,6,12,20-tetrol
g-ppt
20s-protopanaxatriol
20(s)-appt
AKOS030526137
mfcd11041271
Q27896342
(3s,5r,6s,8r,9r,10r,12r,13r,14r,17s)-17-[(2s)-2-hydroxy-6-methylhept-5-en-2-yl]-4,4,8,10,14-pentamethyl-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthrene-3,6,12-triol
hemomex-s
DTXSID30955635
AS-56622
protopanaxatriol
(3s,5r,6s,8r,9r,10r,12r,13r,14r,17s)-17-((r)-2-hydroxy-6-methylhept-5-en-2-yl)-4,4,8,10,14-pentamethylhexadecahydro-1h-cyclopenta[a]phenanthrene-3,6,12-triol

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" The method has been successfully used for the pharmacokinetic studies in rats."( Determination of 20(S)-ginsenoside Rh1 and its aglycone 20(S)-protopanaxatriol in rat plasma by sensitive LC-APCI-MS method and its application to pharmacokinetic study.
Chen, X; Hao, H; Lai, L; Liu, Y; Ren, H; Wang, G, 2009
)
0.35
"To study the pharmacokinetics of ginsenosides Rg1 and its metabolites after iv and oral administration in Wistar rats, the LC-MS/MS method was selected to determine ginsenosides Rg1 and its metabolites in plasma and their pharmacokinetic parameters were calculated."( [Pharmacokinetics of ginsenosides Rg1 and its metabolites in rats].
Feng, L; Hu, CJ; Yu, LY, 2010
)
0.36
" To better understand the differences of pharmacokinetic parameters and metabolism behaviors of Rg3 epimers in rat plasma, a sensitive and specific liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) method was developed and fully validated."( Stereoselective pharmacokinetic and metabolism studies of 20(S)- and 20(R)-ginsenoside Rg₃ epimers in rat plasma by liquid chromatography-electrospray ionization mass spectrometry.
Chen, X; Ding, Y; Le, J; Li, X; Peng, M; Yang, Y; Yi, Y; Zhang, T, 2016
)
0.43

Compound-Compound Interactions

ExcerptReferenceRelevance
"To observe the clinical value of protoparaxotril saporlirs (PTS) combined with aspirin in the secondary prevention of cerebral infarction."( [Clinical value of protoparaxotril saporlirs combined with aspirin in the secondary prevention of cerebral infarction].
Liu, ZF; Xu, ZQ; Zhou, BR, 2008
)
0.35
" As used in combination with aspirin, it shows potential practical importance in the clinical secondary prevention of stroke."( [Clinical value of protoparaxotril saporlirs combined with aspirin in the secondary prevention of cerebral infarction].
Liu, ZF; Xu, ZQ; Zhou, BR, 2008
)
0.35

Bioavailability

ExcerptReferenceRelevance
" Hepatic and intestinal biotransformation of 1α,25(OH)2D3 and modifiers of metabolic capacity could be important determinants of bioavailability in serum and tissues."( Ginsenoside-mediated blockade of 1α,25-dihydroxyvitamin D3 inactivation in human liver and intestine in vitro.
Adomat, H; Chin, MY; Deb, S; Guns, ES, 2014
)
0.4
"Protopanaxatriol and protopanaxadiol exhibit limited oral bioavailability due to the poor solubility and intestinal cytochromes P450-mediated metabolism."( Cytochromes P450 Inhibitory Excipient-Based Self-Microemulsions for the Improved Bioavailability of Protopanaxatriol and Protopanaxadiol: Preparation and Evaluation.
Chang, Q; Hu, X; Liao, Y; Liu, C; Liu, X; Pan, R; Yang, F; Zhou, J, 2017
)
0.46
" Moreover, this study also furnished a strategy for improving the oral bioavailability of different types of ginsenosides by drug combinations."( Effects of schisandra lignans on the absorption of protopanaxadiol-type ginsenosides mediated by P-glycoprotein and protopanaxatriol-type ginsenosides mediated by CYP3A4.
Hu, H; Li, Y; Wang, Z; Xu, C; Yang, K; You, Y; Zhao, L; Zhou, W, 2024
)
1.44
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (6)

ClassDescription
tetracyclic triterpenoidAny triterpenoid consisting of a tetracyclic skeleton.
sapogeninAny organic polycyclic compound that is the aglycon moiety of a saponin; sapogenins may be steroids or triterpenoids.
3beta-hydroxy steroidA 3-hydroxy steroid in which the 3-hydroxy substituent is in the beta-position.
12beta-hydroxy steroid
6alpha-hydroxy steroid
3beta-hydroxy-4,4-dimethylsteroidAny 3beta-hydroxy steroid which is substituted by two methyl groups at position 4.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
ginsenosides biosynthesis225
ginsenosides biosynthesis1032

Bioassays (20)

Assay IDTitleYearJournalArticle
AID1674945Activation of rabbit CK-MM assessed as increase in enzyme activity at 40 uM relative to control2020Bioorganic & medicinal chemistry letters, 09-01, Volume: 30, Issue:17
Structure-activity relationship analysis of dammarane-type natural products as muscle-type creatine kinase activators.
AID1674937Activation of human CK-MM assessed as increase in enzyme activity at 10 uM relative to control2020Bioorganic & medicinal chemistry letters, 09-01, Volume: 30, Issue:17
Structure-activity relationship analysis of dammarane-type natural products as muscle-type creatine kinase activators.
AID1674938Activation of human CK-MM assessed as increase in enzyme activity at 20 uM relative to control2020Bioorganic & medicinal chemistry letters, 09-01, Volume: 30, Issue:17
Structure-activity relationship analysis of dammarane-type natural products as muscle-type creatine kinase activators.
AID1674947Binding affinity to rabbit CK-MM at 20 uM2020Bioorganic & medicinal chemistry letters, 09-01, Volume: 30, Issue:17
Structure-activity relationship analysis of dammarane-type natural products as muscle-type creatine kinase activators.
AID641591Renoprotective activity against AAPH-induced oxidative damage in pig LLC-PK1 cells assessed as cell viability at 1 ug/ml after 24 hrs by MTT assay relative to control2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Protective effect of ginseng sapogenins against 2,2'-azobis (1-aminopropane) dihydrochloride (AAPH)-induced LLC-PK₁ cell damage.
AID1674936Activation of human CK-MM assessed as increase in enzyme activity at 5 uM relative to control2020Bioorganic & medicinal chemistry letters, 09-01, Volume: 30, Issue:17
Structure-activity relationship analysis of dammarane-type natural products as muscle-type creatine kinase activators.
AID641592Renoprotective activity against AAPH-induced oxidative damage in pig LLC-PK1 cells assessed as cell viability at 5 ug/ml after 24 hrs by MTT assay relative to control2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Protective effect of ginseng sapogenins against 2,2'-azobis (1-aminopropane) dihydrochloride (AAPH)-induced LLC-PK₁ cell damage.
AID1255691Cytotoxicity against human HL60 cells after 48 hrs by MTT assay2015Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22
New SIRT1 activator from alkaline hydrolysate of total saponins in the stems-leaves of Panax ginseng.
AID1674940Activation of human CK-MM assessed as increase in enzyme activity at 80 uM relative to control2020Bioorganic & medicinal chemistry letters, 09-01, Volume: 30, Issue:17
Structure-activity relationship analysis of dammarane-type natural products as muscle-type creatine kinase activators.
AID1172986Antiproliferative activity against human MDA-MB-231 cells after 4 hrs by MTT assay2014Bioorganic & medicinal chemistry letters, Dec-01, Volume: 24, Issue:23
Inhibitory effects of ginseng sapogenins on the proliferation of triple negative breast cancer MDA-MB-231 cells.
AID1674944Activation of rabbit CK-MM assessed as increase in enzyme activity at 20 uM relative to control2020Bioorganic & medicinal chemistry letters, 09-01, Volume: 30, Issue:17
Structure-activity relationship analysis of dammarane-type natural products as muscle-type creatine kinase activators.
AID1255693Activation of SIRT1 (unknown origin) after 45 mins by NAD/NADH enzyme-based fluorometric assay2015Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22
New SIRT1 activator from alkaline hydrolysate of total saponins in the stems-leaves of Panax ginseng.
AID641593Renoprotective activity against AAPH-induced oxidative damage in pig LLC-PK1 cells assessed as cell viability at 10 ug/ml after 24 hrs by MTT assay relative to control2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Protective effect of ginseng sapogenins against 2,2'-azobis (1-aminopropane) dihydrochloride (AAPH)-induced LLC-PK₁ cell damage.
AID1255692Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay2015Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22
New SIRT1 activator from alkaline hydrolysate of total saponins in the stems-leaves of Panax ginseng.
AID1674942Binding affinity to recombinant human His-tagged CK-MM at 20 uM by Biolayer Interferometry analysis2020Bioorganic & medicinal chemistry letters, 09-01, Volume: 30, Issue:17
Structure-activity relationship analysis of dammarane-type natural products as muscle-type creatine kinase activators.
AID1674946Activation of rabbit CK-MM assessed as increase in enzyme activity at 80 uM relative to control2020Bioorganic & medicinal chemistry letters, 09-01, Volume: 30, Issue:17
Structure-activity relationship analysis of dammarane-type natural products as muscle-type creatine kinase activators.
AID329594Cell viability of HUVEC cells at 20 ug/ml2008Journal of natural products, Mar, Volume: 71, Issue:3
Antitumor agents. 261. 20(S)-protopanaxadiol and 20(s)-protopanaxatriol as antiangiogenic agents and total assignment of (1)H NMR spectra.
AID401648Cytotoxicity against human BGC823 cells after 48 hrs by MTT assay2005Journal of natural products, May, Volume: 68, Issue:5
Microbial transformation of 20(S)-protopanaxatriol by Mucor spinosus.
AID1674939Activation of human CK-MM assessed as increase in enzyme activity at 40 uM relative to control2020Bioorganic & medicinal chemistry letters, 09-01, Volume: 30, Issue:17
Structure-activity relationship analysis of dammarane-type natural products as muscle-type creatine kinase activators.
AID329593Antiproliferative activity against HUVEC cells after 72 hrs2008Journal of natural products, Mar, Volume: 71, Issue:3
Antitumor agents. 261. 20(S)-protopanaxadiol and 20(s)-protopanaxatriol as antiangiogenic agents and total assignment of (1)H NMR spectra.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (143)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's11 (7.69)18.2507
2000's28 (19.58)29.6817
2010's83 (58.04)24.3611
2020's21 (14.69)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 36.43

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index36.43 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.96 (4.65)
Search Engine Demand Index47.56 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (36.43)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials1 (0.72%)5.53%
Reviews0 (0.00%)6.00%
Reviews3 (2.17%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other9 (100.00%)84.16%
Other134 (97.10%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]